Viral Retinitis following Intraocular or Periocular Corticosteroid Administration: A Case Series and Comprehensive Review of the Literature.

Détails

Ressource 1Télécharger: BIB_5F9BA2536A34.P001.pdf (488.08 [Ko])
Etat: Public
Version: de l'auteur
ID Serval
serval:BIB_5F9BA2536A34
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Viral Retinitis following Intraocular or Periocular Corticosteroid Administration: A Case Series and Comprehensive Review of the Literature.
Périodique
Ocular Immunology and Inflammation
Auteur(s)
Takakura A., Tessler H.H., Goldstein D.A., Guex-Crosier Y., Chan C.C., Brown D.M., Thorne J.E., Wang R., Cunningham E.T.
ISSN
1744-5078 (Electronic)
ISSN-L
0927-3948
Statut éditorial
Publié
Date de publication
2014
Peer-reviewed
Oui
Volume
22
Numéro
3
Pages
175-182
Langue
anglais
Notes
Publication types: JOURNAL ARTICLE
Résumé
Abstract Purpose: To describe viral retinitis following intravitreal and periocular corticosteroid administration. Methods: Retrospective case series and comprehensive literature review. Results: We analyzed 5 unreported and 25 previously published cases of viral retinitis following local corticosteroid administration. Causes of retinitis included 23 CMV (76.7%), 5 HSV (16.7%), and 1 each VZV and unspecified (3.3%). Two of 22 tested patients (9.1%) were HIV positive. Twenty-one of 30 (70.0%) cases followed one or more intravitreal injections of triamcinolone acetonide (TA), 4 (13.3%) after one or more posterior sub-Tenon injections of TA, 3 (10.0%) after placement of a 0.59-mg fluocinolone acetonide implant (Retisert), and 1 (3.3%) each after an anterior subconjunctival injection of TA (together with IVTA), an anterior chamber injection, and an anterior sub-Tenon injection. Mean time from most recent corticosteroid administration to development of retinitis was 4.2 months (median 3.8; range 0.25-13.0). Twelve patients (40.0%) had type II diabetes mellitus. Treatments used included systemic antiviral agents (26/30, 86.7%), intravitreal antiviral injections (20/30, 66.7%), and ganciclovir intravitreal implants (4/30, 13.3%). Conclusions: Viral retinitis may develop or reactivate following intraocular or periocular corticosteroid administration. Average time to development of retinitis was 4 months, and CMV was the most frequently observed agent. Diabetes was a frequent co-morbidity and several patients with uveitis who developed retinitis were also receiving systemic immunosuppressive therapy.
Pubmed
Web of science
Création de la notice
07/04/2014 11:23
Dernière modification de la notice
20/08/2019 15:17
Données d'usage